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Aspirin Is Beneficial in Hypertensive Patients
With Chronic Kidney Disease
A Post-Hoc Subgroup Analysis of a Randomized Controlled Trial
Meg J. Jardine, MBBS, PHD,*† Toshiharu Ninomiya, MD, PHD,* Vlado Perkovic, MBBS, PHD,*
Alan Cass, MBBS, PHD,* Fiona Turnbull, MBBS, PHD,* Martin P. Gallagher, MBBS, MPH,*†
Sophia Zoungas, MBBS, PHD,*‡ Hiddo J. Lambers Heerspink, PHARMD, PHD,*
John Chalmers, MD, PHD,* Alberto Zanchetti, MD§
Sydney and Melbourne, Australia; and Milan, Italy
Objectives The purpose of this study was to determine the benefit and risk associated with antiplatelet therapy in the
chronic kidney disease (CKD) population.
Background Cardiovascular and possibly bleeding risks are elevated in patients with CKD. The balance of benefit and harm
associated with antiplatelet therapy remains uncertain.
Methods The HOT (Hypertension Optimal Treatment) study randomly assigned participants with diastolic hypertension to
aspirin (75 mg) or placebo. Study treatment effects were calculated using univariate proportional hazards re-
gression models stratified by baseline estimated glomerular filtration rate (eGFR) with trends tested by adding
interaction terms. End points included major cardiovascular events, total mortality, and major bleeding.
Results The study included 18,597 participants treated for 3.8 years. Baseline eGFR was 60 ml/min/1.73 m2 in 3,619
participants. Major cardiovascular events were reduced by 9% (95% confidence interval [CI]: 9% to 24%), 15%
(95% CI: 17% to 39%), and 66% (95% CI: 33% to 83%) for patients with baseline eGFR of 60, 45 to 59, and
45 ml/min/1.73 m2, respectively (p trend  0.03). Total mortality was reduced by 0% (95% CI: 20% to
17%), 11% (95% CI: 31% to 40%), and 49% (95% CI: 6% to 73%), respectively (p trend  0.04). Major bleed-
ing events were nonsignificantly greater with lower eGFR (hazard ratio [HR]: 1.52 [95% CI: 1.11 to 2.08], HR:
1.70 [95% CI: 0.74 to 3.88], and HR: 2.81 [95% CI: 0.92 to 8.84], respectively; p trend  0.30). Among every
1,000 persons with eGFR 45 ml/min/1.73 m2 treated for 3.8 years, 76 major cardiovascular events and 54
all-cause deaths will be prevented while 27 excess major bleeds will occur.
Conclusions Aspirin therapy produces greater absolute reduction in major cardiovascular events and mortality in hypertensive
patients with CKD than with normal kidney function. An increased risk of major bleeding appears to be out-
weighed by the substantial benefits. (J Am Coll Cardiol 2010;56:956–65) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.068(
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(hronic kidney disease (CKD) is common in the general
ommunity. Population-based studies have shown that 10%
o 15% of the adult population has CKD (1–3), and this
roportion is increasing (4). Most people with CKD have
elatively mild disease and are unlikely to ever require
ialysis or a kidney transplant; however, even early CKD
onfers an increased risk of cardiovascular events and death
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September 14, 2010:956–65 Aspirin in Chronic Kidney Diseasend benefits associated with other potential preventative
herapies.
In trials of secondary prevention of cardiovascular disease,
reatment with aspirin clearly delivers a net benefit of harm
eduction over harm caused. The Antithrombotic Trialists’
ollaborative Group meta-analysis of individual participant
ata confirmed that aspirin reduces the yearly risk of major
ardiovascular outcomes (strokes and coronary events) by about
5 events per 1,000 patient-years (15). However, the same
nalysis demonstrated that, overall, among participants with no
istory of previous cardiovascular events (primary prevention),
he absolute benefit of aspirin in preventing 0.6 events per
,000 patient-years is comparable to the number of major
astrointestinal and extracranial bleeds caused (0.3 events per
,000 patient-years). Analyses of the effect of aspirin in a
umber of defined subgroups failed to identify a primary
revention patient group that benefited from aspirin.
Patients with CKD have high cardiovascular risk; there-
ore, the absolute benefits of aspirin might be greater for
hem than for people with normal kidney function. How-
ver, patients with CKD have abnormal platelet function,
eaving them at potentially increased hemorrhagic risk when
reated with anticoagulants, including antiplatelet agents
16). Substantial uncertainty persists regarding the balance
etween the risks and benefits associated with antiplatelet
gents for patients with CKD. Consistent with this uncer-
ainty, patients with CKD (17) and end-stage kidney
isease (18) have been shown to be less likely to be
rescribed aspirin after an acute myocardial infarction.
The HOT (Hypertension Optimal Treatment) trial, one
f the largest individual primary prevention trials, randomly
llocated 18,790 participants 50 to 80 years of age with
levated diastolic blood pressure to aspirin or matching
lacebo for an average of 3.8 years (19). It was a primary
revention study with 2% of participants having a prior
istory of myocardial infarction. In the HOT study overall,
significant 15% reduction in major cardiovascular events
1.6 events per 1,000 patient-years) was observed, but this
eeds to be weighed against a significant 80% increase in the
isk of major nonfatal bleeding (1.4 events per 1,000
atient-years). Analyses demonstrated there was no inter-
ction between the blood pressure–lowering effect and
spirin effects (19,20). Subsequent analyses of the HOT
tudy population used serum creatinine thresholds to ex-
lore how impairment of renal function influences the effect
f aspirin (5,6). A trend to increased benefit from aspirin
as demonstrated for patients with an elevated serum
reatinine. However, the balance of benefits and harms
ssociated with aspirin usage in CKD have not been
reviously reported, nor has the level of renal function below
hich benefits may overcome harms been established.
Since these subgroup analyses, estimated glomerular fil-
ration rate (eGFR) using the Modification of Diet in Renal
isease equation (21) has become standard in the staging of
KD (22). This analysis, therefore, investigates whether the
alance of benefits and harms of aspirin therapy in HOT atudy participants is influenced by
idney function evaluated contin-
ously and categorically by CKD
tage based on eGFR levels.
ethods
articipants and HOT trial
esign. The HOT study design
as been described in detail else-
here (19,23). In brief, 18,790
articipants age 50 to 80 years
mean 61.3 years) from 26 coun-
ries in Europe, North and South America, and Asia, and
ith a diastolic blood pressure between 100 and 115 mm
g, were randomly assigned to 2 interventions in a factorial
esign: aspirin 75 mg daily (n 9,399) or matching placebo
n  9,391), and 1 of 3 diastolic blood pressure targets
90, 85, or 80 mm Hg). The blood pressure targets
ere randomly assigned in an open-label fashion. There was
o exclusion on the basis of renal function. The conduct of
he study was overseen by a steering committee and ap-
roved by national and local ethics committees and regula-
ory bodies at all participating centers. An independent
afety committee regularly reviewed safety data. All patients
rovided written informed consent.
The current analysis included 18,597 participants as-
igned to aspirin or placebo for whom baseline serum
reatinine values were available. Analyses of the change in
enal function were performed on participants for whom
erum creatinine values were also available at study end.
lomerular filtration rate was estimated using the 4-variable
odification of Diet in Renal Disease equation (21) and
ategorized using Kidney Disease Outcomes Quality Initia-
ive (KDOQI) stages (24).
nd points. The primary end point of this study was a
omposite of major cardiovascular events consisting of
yocardial infarction, stroke, and death due to cardiovas-
ular disease. Secondary end points included myocardial
nfarction (nonfatal myocardial infarction and death due to
oronary heart disease [including sudden death]), stroke
fatal and nonfatal stroke), cardiovascular mortality, total
ortality, death due to kidney failure, and change in eGFR.
ardiovascular and mortality events were reviewed and
alidated by an independent clinical event committee. Sec-
ndary end points also included investigator-reported major
emorrhage (fatal, life-threatening, disabling, or requiring
ospital admission) and minor hemorrhage (all other re-
orted bleeding events). The first event of each relevant
utcome type was included for analysis.
Participants were recruited from October 1992 until
pril 1994, with follow-up concluding in August 1997,
esulting in an average follow-up period of 3.8 years (range
.3 to 4.9 years) (19).
tatistical methods. The risk estimates for each outcome
Abbreviations
and Acronyms
CI  confidence interval
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
KDOQI  Kidney Disease
Outcomes Quality Initiativessociated with eGFR at baseline were estimated using a
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Aspirin in Chronic Kidney Disease September 14, 2010:956–65ox proportional hazards regression model after adjusting
or potentially confounding baseline covariates including
ge, sex, systolic blood pressure, history of diabetes mellitus,
istory of cardiovascular disease, total cholesterol, body
ass index, and smoking. The variances of each risk
stimate were calculated using the floating absolute risk
ethod (25,26). The regression lines for the risk estimates
ccording to eGFR at baseline were fitted using linear
egression analysis with inverse variance weighting (27).
The effect of randomization to aspirin was assessed
ccording to baseline eGFR categories of 60, 45 to 59
KDOQI CKD stage 3a), and 45 ml/min/1.73 m2
KDOQI stage 3b, 4, and 5). The hazard ratio (HR) and
5% confidence interval (CI) associated with active treat-
ent for each end point was estimated using a univariate
ox proportional hazards regression model stratified by
GFR levels at baseline. The presence of heterogeneity in
he treatment effect across eGFR categories was assessed by
dding an interaction term to the relevant Cox model.
To assess whether there was any threshold level of eGFR,
elow which the effect of treatment changed, the risk
stimate was investigated by fitting univariate Cox propor-
ional hazards model below an eGFR threshold, which was
rogressively changed using 3 ml/min/1.73 m2 increments.
aseline Characteristics of Participants According to eGFR CategoTable 1 Baseline Characteristics of Participants According to e
Overall
>60
Aspirin
(n  7,517)
Placebo
(n  7,461)
eGFR, ml/min/1.73 m2 77 (69–88) 77 (69–89)
Serum creatinine, mol/l 81 (71–93) 81 (71–93)
Characteristics at baseline
Age, yrs 60.6 7.2 60.6 7.2
Female 3,185 (42) 3,197 (43)
Systolic BP, mm Hg 169 14 169 14
Diastolic BP, mm Hg 105 3 105 3
Total cholesterol, mmol/l 6.0 1.1 6.0 1.1
Body mass index, kg/m2 28.4 4.6 28.4 4.6
Diabetes mellitus 578 (8) 600 (8)
Previous myocardial infarction 109 (1) 103 (1)
Previous other coronary heart disease 425 (6) 424 (6)
Previous stroke 78 (1) 72 (1)
Current smokers 1,274 (17) 1,282 (17)
History of ACE inhibitor use 1,442 (19) 1,546 (21)
History of beta-blocker use 1,122 (15) 1,114 (15)
History of calcium-channel blocker use 1,637 (22) 1,587 (21)
History of diuretic use 1,225 (16) 1,262 (17)
History of other BP-lowering agent use 410 (5) 407 (5)
History of use of 2 BP-lowering agents 1,540 (20) 1,583 (21)
Trial assignment
More intensive BP treatment 2,509 (33) 2,465 (33)
Blood pressure during follow-up, mm Hg
Systolic BP achieved 142 12 141 12
Diastolic BP achieved 84 5 83 5alues are median (interquartile range), mean  SD, or n (%).
ACE  angiotensin-converting enzyme; BP  blood pressure; eGFR  estimated glomerular filtration rThe absolute effect of randomization to aspirin was
alculated as the number of people in whom events were
revented or caused per 1,000 patients treated for 3.8 years
or the overall study population and for categories of kidney
unction.
esults
he study population, consisting of 18,597 of 18,790
99.0%) randomized patients with serum creatinine data
vailable, had a median eGFR of 73 ml/min/1.73 m2
interquartile range 63 to 84 ml/min/1.73 m2). Of these,
4,978 (80.5%) had an eGFR 60 ml/min/1.73 m2, 3,083
16.6%) had an eGFR of 45 to 59 ml/min/1.73 m2, and 536
2.9%) an eGFR of 45 ml/min/1.73 m2 (Table 1). Only 9
atients (0.05%) had an eGFR of 15 ml/min/1.73 m2.
A total of 671 people experienced at least 1 major
ardiovascular event. Strokes were experienced by 289 par-
icipants, and myocardial infarctions were experienced by
49. There were 582 deaths from any cause, including 268
eaths from cardiovascular causes and 8 from renal failure
3 in the aspirin group and 5 in the placebo group). There
ere 15 fatal bleeding events (7 in the aspirin group and 8
and Aspirin RandomizationCategories and Aspirin Randomization
eGFR (ml/min/1.73 m2)
45–59 <45
Aspirin
(n  1,527)
Placebo
(n  1,556)
Aspirin
(n  264)
Placebo
(n  272)
55 (52–58) 55 (52–58) 40 (34–43) 39 (32–43)
99 (92–115) 100 (93–115) 142 (121–174) 150 (121–177)
65.0 7.5 64.9 7.5 66.1 8.2 66.1 7.9
,036 (68) 1,026 (66) 169 (64) 175 (64)
171 15 171 14 173 16 173 16
105 3 105 3 105 3 105 3
6.2 1.2 6.2 1.2 6.2 1.3 6.1 1.1
28.4 4.7 28.6 4.9 28.5 5.3 28.6 4.9
138 (9) 110 (7) 31 (12) 31 (11)
28 (2) 27 (2) 6 (2) 9 (3)
109 (7) 113 (7) 18 (7) 18 (7)
24 (2) 31 (2) 9 (3) 6 (2)
160 (10) 168 (11) 39 (15) 30 (11)
318 (21) 364 (23) 80 (30) 56 (21)
247 (16) 222 (14) 40 (15) 41 (15)
394 (26) 373 (24) 81 (31) 81 (30)
311 (20) 350 (23) 63 (24) 63 (23)
97 (6) 90 (6) 22 (8) 27 (10)
377 (25) 412 (26) 83 (31) 81 (30)
515 (34) 543 (35) 76 (29) 86 (32)
143 12 142 12 145 14 143 12
83 5 83 5 83 6 82 6riesGFR
1ate.
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September 14, 2010:956–65 Aspirin in Chronic Kidney Diseasen the placebo group), 187 nonfatal major bleeding events,
nd 208 minor bleeding events.
ardiovascular events and bleeding in subjects with
idney disease. Patients with lower eGFR levels experienced
reater rates of cardiovascular events, bleeding events, and
eath: major cardiovascular event rates were 32.2, 46.4, and
0.2 per 1,000 patients with eGFR 60, 45 to 59, and 45
l/min/1.73 m2, respectively; myocardial infarction rates were
7.2, 22.7, and 39.2 per 1,000 patients; stroke rates were 13.3,
3.4, and 31.7 per 1,000 patients; cardiovascular mortality rates
ere 12.6, 18.5, and 42.9 per 1,000 patients; major bleeding
vent rates were 10.8, 7.8, and 28.0 per 1,000 patients; and
otal mortality rates were 29.1, 32.8, and 84.0 per 1,000
atients. Event rates were increased by 70% to 100% for every
Figure 1 Increase in HR With Decline in eGFR
Hazard ratio (HR) for any cardiovascular event, myocardial infarctions, strokes, cardiov
glomerular filtration rate (eGFR) declines, according to Kidney Disease Outcomes Qua
CI  confidence interval.alving of eGFR: major cardiovascular events (HR: 1.84, 95%
I: 1.37 to 2.46), myocardial infarctions (HR: 1.84, 95% CI:
.09 to 3.11), stroke (HR: 1.87, 95% CI: 1.28 to 2.73),
ardiovascular mortality (HR: 1.99, 95% CI: 1.32 to 2.99),
leeding events (HR: 1.77, 95% CI: 1.09 to 2.86), and total
ortality (HR: 1.69, 95% CI: 0.82 to 3.49) (Fig. 1).
ffect of aspirin according to categories of reduced
idney function. MAJOR CARDIOVASCULAR EVENTS. As
reviously reported (19), aspirin significantly reduced the
isk of major cardiovascular events for the overall study
opulation for whom creatinine measurements were avail-
ble (event rates for active and placebo groups were 3.32%
nd 3.90%, respectively; HR: 0.85, 95% CI: 0.73 to 0.98).
he benefit provided by aspirin was significantly greater for
r mortality, total mortality, and bleeding incidence increases as estimated
ative categories of eGFR (median eGFR for Stage 0/1, 2, 3a, 3b, and 4 depicted).ascula
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Aspirin in Chronic Kidney Disease September 14, 2010:956–65ubjects with low eGFR: risk reductions of 9% (HR: 0.91,
5% CI: 0.76 to 1.09), 15% (HR: 0.85, 95% CI: 0.61 to
.17), and 66% (HR: 0.34, 95% CI: 0.17 to 0.67) were
bserved for patients with eGFR 60, 45 to 60, and 45
l/min/1.73 m2, respectively (p for interaction  0.03)
Fig. 1). Event rates for subjects treated with aspirin fell from
.38% to 3.10% for those with eGFR 60 ml/min/1.73 m2,
rom 5.01% to 4.26% for those with eGFR 45 to 60 ml/min/
.73 m2, and from 11.76% to 4.17% for those with eGFR45
l/min/1.73 m2 over the mean 3.8 follow-up years in the
tudy. There was no interaction between assignment to differ-
nt diastolic blood pressure targets and assignment to aspirin
all p values for interaction  0.2; data not shown).
ECONDARY END POINTS. The protection afforded by aspi-
in for myocardial infarction increased as kidney function
eclined (Fig. 2), although the interaction was of borderline
tatistical significance (p  0.08). Subjects with the highest
Figure 2 Effect of Aspirin According to eGFR Category
Effect of randomized aspirin on outcomes according to estimated glomerular filtratGFR (60 ml/min/1.73 m2) had a borderline significant
isk reduction of 22% (HR: 0.78, 95% CI: 0.61 to 1.00),
ubjects with an eGFR of 45 to 59 ml/min/1.73 m2 had a
isk reduction of 36% (HR: 0.64, 95% CI: 0.39 to 1.03), and
ubjects with eGFR 45 ml/min/1.73 m2 had a risk
eduction of 69% (HR: 0.31, 95% CI: 0.11 to 0.85). Event
ates for subjects treated with aspirin fell from 1.93% to
.52% for those with eGFR 60 ml/min/1.73 m2, from
.76% to 1.77% for those with eGFR 45 to 60 ml/min/1.73
2, and from 5.88% to 1.89% for those with eGFR 45
l/min/1.73 m2 over the mean 3.8 follow-up years in the
tudy.
There was no significant benefit in the total study
opulation from aspirin therapy for total mortality, cardio-
ascular mortality, or stroke (Fig. 2). However, aspirin did
onfer significant protection for subjects with an eGFR
45 ml/min/1.73 m2 for whom total mortality was reduced
e (eGFR) category. CI  confidence interval.ion rat
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September 14, 2010:956–65 Aspirin in Chronic Kidney Diseasey roughly one-half (event rates for active and placebo
roups 11.03% and 5.68%, respectively; HR: 0.51, 95% CI:
.27 to 0.94), cardiovascular mortality by nearly two-thirds
event rates for active and placebo groups 6.25% and 2.27%,
espectively; HR: 0.36, 95% CI: 0.14 to 0.90), and stroke by
early four-fifths (event rates for active and placebo groups
.15% and 1.14%, respectively; HR: 0.21, 95% CI: 0.06 to
.75). The benefit for cardiovascular mortality and total
ortality was significantly greater for patients with reduced
idney function than for subjects with normal kidney
unction (p for both interactions  0.04) and was nearly
ignificantly greater for stroke (p for interaction  0.06).
IDNEY FUNCTION DEFINES THRESHOLDOF ASPIRIN BENEFIT.
e performed sensitivity analyses to identify any eGFR
hreshold level below which the benefit associated with
spirin therapy changed and to confirm that our analyses did
ot appear vulnerable to adjustments in the cut-off between
he eGFR categories. The benefit from aspirin therapy
rogressively, but not linearly, increased (declining risk ratio
mong subjects randomly assigned to aspirin therapy) as
GFR declined for all end points (Fig. 3). However, the
isk reduction of aspirin therapy for cardiovascular mortality,
otal mortality, and stroke became large and significant when
aseline eGFR was 45 ml/min/1.73 m2.
ARMS OF ASPIRIN ACCORDING TO eGFR CATEGORY. In
he overall study population, aspirin increased the risk of
ajor bleeding by 61% (HR: 1.61, 95% CI: 1.21 to 2.14)
Fig. 4). The risk of major bleeding associated with aspirin
as nonsignificantly greater with categories of lower eGFR
HR: 2.81, 95% CI: 0.90 to 8.84 for eGFR 45 ml/min/
.73 m2; HR: 1.70, 95% CI: 0.74 to 3.88 for eGFR 45 to 59
l/min/1.73 m2; and HR: 1.52, 95% CI: 1.11 to 2.08 for
GFR 60 ml/min/1.73 m2; p trend  0.30). There were
5 fatal bleeds in the study, 7 among subjects assigned
spirin therapy and 8 among subjects assigned placebo. All
atal bleeds were in subjects with an eGFR 60 ml/min/
.73 m2. There was a trend toward an increased risk of
ny bleeding as categories of eGFR declined, although
he absolute numbers of events in subjects with reduced
idney function were few (p for interaction  0.08).
here was no interaction between assignment to different
iastolic blood pressure targets and assignment to aspirin (all
values for interaction  0.2; data not shown).
et absolute effect. Overall, 6 major cardiovascular events
ill be prevented for every 1,000 participants treated for 3.8
ears, while there will be 6 major bleeds and 6 minor bleeds
Table 2). Both the benefits and risks increase as kidney
unction declines, with the net benefit appearing to increase.
or every 1,000 people with eGFR 45 ml/min/1.73 m2
reated with aspirin for 3.8 years, 76 people will avoid a
ajor cardiovascular event, and 40 myocardial infarctions,
0 strokes, 40 cardiovascular deaths, and 54 all-cause deaths
ill be prevented. Conversely, 27 major bleeding episodes lnd 12 minor bleeding episodes would be caused by aspirin
herapy for persons with an eGFR 45 ml/min/1.73 m2.
ffect of aspirin on kidney function. Aspirin therapy did
ot affect renal function in the overall study population nor
ithin any eGFR category (Table 3).
iscussion
afe treatments to reduce the high risk of cardiovascular
isease for patients with CKD are urgently required. In this
nalysis, we confirm that aspirin therapy prevented signifi-
antly more cardiovascular events, cardiovascular deaths,
nd all-cause deaths in patients with CKD than in subjects
ith normal kidney function. Aspirin therapy had no
etrimental effect on renal function. Although the absolute
isk of bleeding was greater for subjects with CKD, the
verall cardiovascular benefits appear to outweigh bleeding
isks. These results suggest that primary prevention with
spirin reduces the burden of cardiovascular disease and has
n overall net benefit among high-risk patients with CKD.
Our analysis confirms previous findings in the HOT
tudy population and in other studies that cardiovascular
isk increases with declining CKD stage (5–7,28,29). Over-
ll, the HOT study participants were at low risk, with a
-year rate of myocardial infarction of 2.9% and of major
ardiovascular events of 5.1%, observed in the control arm.
owever, the HOT study participants with stage 3b CKD
andomly assigned to placebo had a 5-year myocardial
nfarction rate of 7.7%, with a 5-year major cardiovascular
vent rate of 15.5%. These high event rates underscore the
eed for a clear understanding of the risks and benefits of
otentially effective preventative therapies.
Aspirin appears to produce greater absolute benefits for
atients with CKD. The explanation for this greater benefit
ies partly in the high baseline risk of these patients,
ranslating a similar proportional benefit into a greater
bsolute benefit. In addition, the current analysis demon-
trates greater proportional benefits with progressively lower
GFR. The explanation for this difference in proportional
enefit is unclear. Patients with advanced CKD are known
o have abnormal platelet function and evidence of a
redisposition to both thrombotic and bleeding events.
atients with all stages of CKD (30–33) have higher rates
f thromboembolism than the general population. Con-
ersely, patients with kidney disease appear to have an
ncreased bleeding risk, with evidence in advanced kidney
isease of decreased platelet aggregation and of a range of
latelet abnormalities (34–37). Observational and random-
zed clinical studies in dialysis patients sometimes (38), but
ot always, report increased bleeding rates with antiplatelet
herapy (39–41), although some of these studies excluded
hose at high bleeding risk.
There are few other randomized trials describing the
ffects of antiplatelet therapy involving substantial numbers
f subjects with CKD. The Antithrombotic Trialists’ Col-
aborative Group reported the results of an individual
962 Jardine et al. JACC Vol. 56, No. 12, 2010
Aspirin in Chronic Kidney Disease September 14, 2010:956–65Figure 3 Effect of Aspirin on End Points
The effects of aspirin treatment on end points in the subgroup below each cut-off value of estimated glomerular filtration rate (eGFR). CI  confidence interval.
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September 14, 2010:956–65 Aspirin in Chronic Kidney Diseaseatient data meta-analysis of antiplatelet therapy that in-
luded 99 cardiovascular events in 2,632 hemodialysis pa-
ients. They found a 41% odds reduction (SE 16%) in the
isk of cardiovascular events among hemodialysis patients
40), compared with a 22% odds reduction (SE 2%) seen in
he overall study population, although the difference was not
tatistically significant. The efficacy and harm of aspirin and
ther antiplatelet agents may not be homogeneous. Post-
oc analyses of the effect of additional clopidogrel over
tandard therapy according to GFR categories has shown a
enefit consistent with that in the population with normal
enal function in some (42) but not all (29) studies. For
Figure 4 Effect of Aspirin on Bleeding Rates
Effect of randomization to aspirin on bleeding rates according to
estimated glomerular filtration rate (eGFR) category. CI  confidence interval.
Events Prevented and Caused by Aspirin Therap1,000 Patients Treated According to eGFR CateTable 2 Ev nts Prevent a d Caused by As1,000 Patients Treated According t
>60
Events prevented by aspirin therapy
Major cardiovascular events 3 (3 to 8)
Myocardial infarctions 4 (0 to 8)
Stroke 1 (5 to 2)
Cardiovascular mortality 1 (5 to 3)
Total mortality 0 (5 to 5)
Events caused by aspirin therapy
Major bleeding 4 (1 to 8)
Minor bleeding 4 (1 to 8)
Any bleeding 8 (3 to 12)Values are absolute risk change (95% confidence interval) per 1,000 patient
eGFR  estimated glomerular filtration rate.atients with diabetes and albuminuria, the addition of
lopidogrel to aspirin was associated with increased mortal-
ty not seen in nonalbuminuric diabetic patients or nondi-
betic patients in a post-hoc analysis (43).
This analysis has some important limitations. Only 2.9%
f the study population had an eGFR45 ml/min/1.73 m2,
imiting our power to estimate bleeding risk in this group.
he small number of participants with CKD stage 4 and
bove (98 had an eGFR 30 ml/min/1.73 m2) mean the
ndings cannot be extrapolated to patients with severe
KD or end-stage kidney disease. In addition, the HOT
tudy, as in many randomized trials of aspirin administra-
ion, did not report bleeding episodes with the same
recision as cardiovascular outcomes, and bleeding episodes
ere not validated by an expert committee. Furthermore,
his is a post-hoc analysis of a trial that was not designed (or
owered) to examine the effects of aspirin according to
ategories of kidney function. Finally, the participants in
his trial were at increased cardiovascular risk due to the
lood pressure–based entry criteria, meaning extrapolation
o persons with normal blood pressure levels is not possible.
Our results indicate that CKD predicts increased cardio-
ascular risk and greater net benefit with aspirin therapy.
EveryTherapy for Every
FR Category
R, ml/min/1.73 m2
Overall45–59 <45
8 (7 to 22) 76 (31 to 121) 6 (0 to 11)
10 (1 to 20) 40 (7 to 72) 6 (2 to 10)
0 (11 to 10) 40 (11 to 69) 0 (3 to 4)
2 (8 to 11) 40 (6 to 74) 1 (3 to 4)
4 (9 to 17) 54 (7 to 100) 2 (3 to 7)
4 (2 to 10) 27 (1 to 55) 6 (3 to 8)
12 (3 to 21) 12 (8 to 31) 6 (2 to 9)
16 (5 to 27) 39 (5 to 72) 10 (6 to 14)
ifference in Change in Renal Function Duringollow-Up Between Group R ndomized to Aspirinnd Group Randomized to Pl cebo, Acc rding toGFR Categories
Table 3
Difference in Change in Renal Function During
Follow-Up Between Group Randomized to Aspirin
and Group Randomized to Placebo, According to
eGFR Categories
eGFR Levels at Baseline
(ml/min/1.73 m2)
Annual Change in eGFR During Follow-Up
for Aspirin Group Versus Placebo Group
(ml/min/1.73 m2 yr)
Mean (95% Confidence Interval)* p Value
eGFR60 0.16 (0.33 to 0.01) 0.06
eGFR 45–59 0.08 (0.37 to 0.21) 0.57
eGFR45 0.30 (0.74 to 1.34) 0.57
Overall 0.15 (0.30 to 0.00) 0.06
The difference in the annual changing rate of estimated glomerular filtration rate (eGFR) during
ollow-up was estimated by subtracting the mean annual changing rate of eGFR in the placebo
roup from that in the aspirin group. Negative value indicates greater reduction in eGFR during
ollow-up in the aspirin group than the placebo group.y forgorypirin
o eG
eGFs treated for an average of 3.8 years.
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Aspirin in Chronic Kidney Disease September 14, 2010:956–65his finding reinforces calls to consider CKD when making
ecisions regarding treatment to mitigate cardiovascular
isk. These results suggest that aspirin might be used more
idely as primary prevention for high-risk patients with
KD.
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